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Introduction
Familial Mediterranean fever (FMF) is an autoinflamma-
tory disorder, characterized by periodic fever and serosal
inflammation. Colchicine is effective in controlling the
attacks and preventing the development of amyloidosis.
About 5-10% of the patients do not respond to colchicine.
Objectives
In this study it was aimed to determine the set of criteria
for the diagnosis of resistance to colchicine.
Methods
This study was planned with Delphi technique sent to 70
experts on FMF and 59 of them approved to attend. In the
first Delphi round, clinical and laboratory findings indicat-
ing colchicine resistance and the protocol which would
define resistance to treatment and exclusion criteria were
defined. Based on the results of the first Delphi, a second
Delphi form which included 5 evaluation questions was
developed. In this latter form the questions to be used in
order to define complete response, partial response and
non-response were tried to be determined.
Results
In the first Delphi round, persistence of the frequency,
severity and the duration of episodes in spite of the treat-
ment with adequate dosage ranked the highest. Laboratory
findings that are thought as the best indicator of resistance
to treatment were high levels of acute phase reactants (In
order of frequency; CRP, ESR, SAA and fibrinogen).
In the second Delphi round, among 57 experts, 35
experts reported the frequency of attacks while 10 experts
reported the duration and 9 reported the severity of the
disease as an indicator for the assessment of response to
colchicine treatment.
For a complete response, normal CRP levels were
required by 54 experts while 43 experts reported that 50%
decrease in CRP levels could be accepted as partial
response to treatment. Appropriate duration for the
assessment of response to colchicine treatment was deter-
mined as 3 to 6 months by 34 experts. It was also stated
that the highest dose for age and weight should be given
in order to state colchicine resistance. Thirty three experts
stated that the patient should be attack free for a complete
response to colchicine treatment. For defining the partial
response to treatment, a 50% decrease in attack frequency
was the most favored choice.
Conclusion
Assessing the colchicine resistance via concrete and agreed
scale will provide a reliable data. The study is to be fina-
lized soon with an expert panel.
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